Abstract:Introduction: Epigenetic-targeted therapy has been increasingly applied in the treatment of cancers. Lysine (K)-specific demethylase 6B (KDM6B) is an epigenetic enzyme involved in the coordinated control between cellular intrinsic regulators and the tissue microenvironment whereas the pan-cancer analysis of KDM6B remains unavailable. Methods: The dual role of KDM6B in 33 cancers was investigated based on the GEO (Gene Expression Omnibus) and TCGA (The Cancer Genome Atlas) databases. TIMER2 and GEPIA2 were applied to investigate the KDM6B levels in different subtypes or stages of tumors. Besides, the Human Protein Atlas database allowed us to conduct a pan-cancer study of the KDM6B protein levels. GEPIA2 and Kaplan–Meier plotter were used for the prognosis analysis in different cancers. Characterization of genetic modifications of the KDM6B gene was analyzed by the cBioPortal. DNA methylation levels of different KDM6B probes in different TCGA tumors were analyzed by MEXPRESS. TIMER2 was applied to determine the association of the KDM6B expression and immune infiltration and DNA methyltransferases. Spearman correlation analysis was used to assess the association of the KDM6B expression with TMB (tumor mutation burden) and MSI (microsatellite instability). The KEGG (Kyoto encyclopedia of genes and genomes) pathway analysis and GO (Gene ontology) enrichment analysis were used to further investigate the potential mechanism of KDM6B in tumor pathophysiology. Results: KDM6B was downregulated in 11 cancer types and upregulated across five types. In KIRC (kidney renal clear cell carcinoma) and OV (ovarian serous cystadenocarcinoma), the KDM6B level was significantly associated with the pathological stage. A high level of KDM6B was related to poor OS (overall survival) outcomes for THCA (thyroid carcinoma), while a low level was correlated with poor OS and DFS (disease-free survival) prognosis of KIRC. The KDM6B expression level was associated with TMB, MSI, and immune cell infiltration, particularly cancer-associated fibroblasts, across various cancer types with different correlations. Furthermore, the enrichment analysis revealed the relationship between H3K4 and H3K27 methylation and KDM6B function. Conclusion: Dysregulation of the DNA methyltransferase activity and methylation levels of H3K4 and H3K27 may involve in the dual role of KDM6B in tumorigenesis and development. Our study offered a relatively comprehensive understanding of KDM6B's dual role in cancer development and response to immunotherapy.

Targeting Histone Demethylase KDM5B for Cancer Treatment.

Targeting histone demethylase KDM5B for cancer treatment

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Pharmacological inhibition of KDM5A for cancer treatment

The emerging role of KDM5A in human cancer

Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target

KDM4B: A promising oncology therapeutic target

The Diverse Roles of Histone Demethylase KDM4B in Normal and Cancer Development and Progression

The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities

An Inhibitor of KDM5 Demethylases Reduces Survival of Drug-Tolerant Cancer Cells.

Progress in Research of KDM5C in Human Tumors

Small Molecule KDM4s Inhibitors As Anti-Cancer Agents

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Function of Histone Demethylasehistone Lysine-Specific Demethylase 1A in Tumor Initiation and Progression

The PHD1 Finger of KDM5B Recognizes Unmodified H3K4 During the Demethylation of Histone H3K4me2/3 by KDM5B

A Pan-Cancer Analysis Revealing the Dual Roles of Lysine (K)-Specific Demethylase 6B in Tumorigenesis and Immunity

Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications

Discovery of Pyrazole Derivatives As Cellular Active Inhibitors of Histone Lysine Specific Demethylase 5B (KDM5B/JARID1B).

Research progress in histone lysine demethylases inhibitors

H3K4 demethylase KDM5B regulates cancer cell identity and epigenetic plasticity